Karl Cahill
Fondateur chez MOSS GENOMICS INC.
Fortune : 76 500 $ au 30/04/2024
Profil
Karl Cahill is the founder and current Chief Executive Officer & Director of Moss Genomics, Inc., which is founded in 2018.
He was previously the Vice President-Investor Relations at Concordia Resource Corp.
from 2011 to 2012, and held the position of Head-Investor Relations at Raptor Pharmaceuticals Corp.
and Vice President-Investor Relations at AbraSilver Resource Corp.
Mr. Cahill completed his undergraduate degree at the University of Westminster.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MOSS GENOMICS, INC.
5,70% | 22/02/2023 | 2 550 000 ( 5,70% ) | 76 500 $ | 30/04/2024 |
Postes actifs de Karl Cahill
| Sociétés | Poste | Début |
|---|---|---|
| MOSS GENOMICS INC. | Fondateur | 25/09/2018 |
Anciens postes connus de Karl Cahill
| Sociétés | Poste | Fin |
|---|---|---|
Concordia Resource Corp.
 Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Investor Relations Contact | 16/08/2012 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Public Communications Contact | 01/10/2009 |
| ABRASILVER RESOURCE CORP. | Investor Relations Contact | - |
Formation de Karl Cahill
| University of Westminster | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABRASILVER RESOURCE CORP. | Non-Energy Minerals |
| MOSS GENOMICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Concordia Resource Corp.
Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |